The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

Precision metagenomics: a rapid solution for identifying and characterizing microbial agents of infectious disease.
Editor's Choice

Precision metagenomics: a rapid solution for identifying and characterizing microbial agents of infectious disease.

OCT 17, 2024
Sequential Launches Industry-First Microbiome Target Panels for Skin Conditions
Pharma & Human Health

Sequential Launches Industry-First Microbiome Target Panels for Skin Conditions

OCT 16, 2024
A potential non-invasive stool test and novel therapy for endometriosis
Pharma & Human Health

A potential non-invasive stool test and novel therapy for endometriosis

OCT 16, 2024
Exhaling Clues to the Activity of the Microbiome with Owlstone’s Breath Biopsy Technology – An Interview with Dr. Liz Crone
Editor's Choice

Exhaling Clues to the Activity of the Microbiome with Owlstone’s Breath Biopsy Technology – An Interview with Dr. Liz Crone

OCT 15, 2024
Lesaffre acquires Altar, an Adaptive Laboratory Evolution start-up from Ginkgo Bioworks
Finance

Lesaffre acquires Altar, an Adaptive Laboratory Evolution start-up from Ginkgo Bioworks

OCT 7, 2024
dsm-firmenich completes the sale of yeast extract business to Lesaffre
Finance

dsm-firmenich completes the sale of yeast extract business to Lesaffre

OCT 2, 2024
Ostia Sciences Inc. Secures Seed Investment, Finalizes IP and Prepares Microbiome Technology Prototype 
Finance

Ostia Sciences Inc. Secures Seed Investment, Finalizes IP and Prepares Microbiome Technology Prototype 

OCT 2, 2024
Florey Biosciences spins out of Harvard Wyss Institute to develop a medical food aimed at managing impacts of antibiotic use
Finance

Florey Biosciences spins out of Harvard Wyss Institute to develop a medical food aimed at managing impacts of antibiotic use

OCT 1, 2024
EMIH and MTIG join forces with Microbiome Times on important deal-making event, taking place Brussels 2025
Editor's Choice

EMIH and MTIG join forces with Microbiome Times on important deal-making event, taking place Brussels 2025

SEP 25, 2024
Next-Generation Sequencing for Microbial Community Profiling
Pharma & Human Health

Next-Generation Sequencing for Microbial Community Profiling

SEP 25, 2024
Webinar

Microbial Community Profiling Webinar

SEP 25, 2024